SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 mln in US IPO

Biopharmaceutical firm Neumora Therapeutics, backed by Amgen AMGN.O and Japan's SoftBank 9984.T, is aiming to raise up to $264.8 million in its U.S. initial public offering, according to a regulatory filing on Monday.